StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Total stock-based compensation expense recognized in by Quarter

Total stock-based compensation (SBC) expense recognized in income statement ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Total stock-based compensation expense recognized in: $170M in Q2 2026, up 1.7% from a year earlier.

Latest, Q2 2026
170
Period ended Jun 30, 2026
Change on a year earlier
+1.7%
167 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
41
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note (Stock-based Compensation).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal stock-based compensation (SBC) expense recognized in income statement ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026170+1.7%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 2026166+0.2%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 2025158-6.1%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025195+5.6%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025167+8.5%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 2025166-13.4%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 2024168-19.6%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024185+41.0%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 2024154+29.3%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 2024192+56.8%Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023209+87.1%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023131-3.5%Form 10-Q (filed 2024-11-05) ↗
Q2 2023Jun 30, 2023119+4.7%Form 10-Q (filed 2024-08-02) ↗
Q1 2023Mar 31, 2023122-6.1%Form 10-Q (filed 2024-05-07) ↗
Q4 2022Dec 31, 2022112-6.0%Form 10-K (filed 2025-02-13) ↗
Q3 2022Sep 30, 2022136+31.7%Form 10-Q (filed 2023-11-07) ↗

Breakdown

What makes up total stock-based compensation expense recognized in

Cite this data

StockData. (2026). Vertex Pharmaceuticals Total stock-based compensation expense recognized in ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-exp-tot

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.